Valeant Pharmaceuticals International
Tel: 800-548-5100 or 949-461-6000
About Valeant Pharmaceuticals InternationalValeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
CEO: Joseph C. Papa
CMO: Tage Ramakrishna
CFO: Robert Rosiello
Please click here for clinical trial information.
Please click here for Valeant job opportunities.
945 articles with Valeant Pharmaceuticals International
Bausch Health Will Begin Trading as "BHC" on NYSE and TSX on Monday, July 16
Bausch + Lomb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its sub-micron loteprednol etabonate ophthalmic gel
Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.
After failing to gain market share under the umbrella of Valeant Pharmaceuticals, Addyi is getting a relaunch at half the price.
Ortho Dermatologics, a division of Quebec-based Valeant Pharmaceuticals International, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Duobrii for plaque psoriasis.
Ortho Dermatologics announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for DUOBRII™1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis.
Bausch + Lomb announced the introduction of Soothe® Xtra Protection (XP) Preservative Free lubricant eye drops
Bausch + Lomb announced the introduction of Ocuvite® Blue Light eye vitamins
On June 6, 2018, the U.S. Patent & Trademark Office issued a final written decision in favor of Argentum Pharmaceuticals, finding all claims of U.S. Patent No. 7,214,506 to be unpatentable for obviousness.
After two of Allergan’s investors, Appaloosa Management and Senator Investment Group, wrote to the company’s board asking that Brent Saunders’ duties be split up, legendary investor Carl Icahn appears to be building a position in the company—again.
Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes
Valeant Pharmaceuticals International, Inc. announced that it has entered into a Fourth Amended & Restated Credit and Guaranty Agreement effectuating a full refinancing of its secured revolving and term loan credit facilities, and closed the previously announced offering of 8.500% Senior Notes due 2027.
Salix Pharmaceuticals will present new scientific data, including one podium presentation and eight posters evaluating investigative data on the safety and efficacy of XIFAXAN® (rifaximin) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) at Digestive Disease Week (DDW).
A former Valeant Pharmaceuticals and a former Philidor Rx Services have been found guilty of using a kickback scheme to defraud the company.
Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl Investors
Kyros Law Offices is alerting investors of Valeant that it is filling legal claims against the company for possible securities fraud violations committed by Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it is seeking to amend and restate its existing credit agreement (the "Credit Agreement") and borrow $3.815 billion of new Term B loans (the "New Term B Loans") under the Credit Agreement
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Joseph C. Papa, chairman and chief executive officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas on May 16, 2018 at 10:40 a.m. PDT (1:40 p.m. EDT).
Valeant Pharmaceuticals will change its name to Bausch Health Companies Inc. in July of this year. The company will rebrand itself with the highly recognizable name of its subsidiary eye-care company Bausch + Lomb.
Scandals are nothing new in any industry. The pharmaceutical and biotech industry are certainly no strangers to scandals – just ask convicted scandal-magnet Martin Shkreli.
Valeant Pharmaceuticals International, Inc. announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer, is scheduled to participate at the Goldman Sachs Third Annual Leveraged Finance Conference.
Summary Judgment Granted Upholding The Validity Of Formulation Patent Protecting RELISTOR® Injection
Valeant Pharmaceuticals International, Inc. announced that the U.S. District Court for the District of New Jersey has granted a motion for partial summary judgment of validity of a formulation patent for RELISTOR® (methylnaltrexone bromide) Injection.